Javascript must be enabled to continue!
Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons
View through CrossRef
Abstract
Glucagon-like peptide 1 receptor (GLP1R) agonists like semaglutide drive weight loss through the brain, but insights into their intracellular signaling mechanisms are lacking. Although canonically GLP1Rs signal through the stimulatory alpha Gs protein, we find that semaglutide utilizes both Gs- and Gq-signaling pathways in GLP1Rs in the area postrema (AP)—the primary site of semaglutide action in the brain—to differentially regulate neuronal activation across distinct neuronal clusters. Semaglutide also drives graded increases of the essential secondary messenger cyclic adenosine monophosphate (cAMP) in Glp1r-expressing AP neurons (AP
Glp1r
) through Gs-dependent and -independent manners. Inhibition of the cAMP-degradation enzyme phosphodiesterase 4 (PDE4) can enhance and sustain these cAMP responses, whereas disruption of Gs or cAMP signaling in AP
Glp1r
neurons abolishes semaglutide-induced weight loss and downstream brain-wide activation. Our systematic characterization of semaglutide’s signaling mechanisms in the brain provides avenues for improving the performance of obesity therapeutics.
Title: Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons
Description:
Abstract
Glucagon-like peptide 1 receptor (GLP1R) agonists like semaglutide drive weight loss through the brain, but insights into their intracellular signaling mechanisms are lacking.
Although canonically GLP1Rs signal through the stimulatory alpha Gs protein, we find that semaglutide utilizes both Gs- and Gq-signaling pathways in GLP1Rs in the area postrema (AP)—the primary site of semaglutide action in the brain—to differentially regulate neuronal activation across distinct neuronal clusters.
Semaglutide also drives graded increases of the essential secondary messenger cyclic adenosine monophosphate (cAMP) in Glp1r-expressing AP neurons (AP
Glp1r
) through Gs-dependent and -independent manners.
Inhibition of the cAMP-degradation enzyme phosphodiesterase 4 (PDE4) can enhance and sustain these cAMP responses, whereas disruption of Gs or cAMP signaling in AP
Glp1r
neurons abolishes semaglutide-induced weight loss and downstream brain-wide activation.
Our systematic characterization of semaglutide’s signaling mechanisms in the brain provides avenues for improving the performance of obesity therapeutics.
Related Results
ABHD17A-driven GLP1R depalmitoylation rewired G-protein coupling to impair periodontal ligament stem cell homeostasis in periodontitis
ABHD17A-driven GLP1R depalmitoylation rewired G-protein coupling to impair periodontal ligament stem cell homeostasis in periodontitis
<b>Background and Purpose:</b> Periodontitis combines persistent inflammation with impaired periodontal regeneration. We investigated whether post-translational modific...
ABHD17A-driven GLP1R depalmitoylation rewired G-protein coupling to impair periodontal ligament stem cell homeostasis in periodontitis
ABHD17A-driven GLP1R depalmitoylation rewired G-protein coupling to impair periodontal ligament stem cell homeostasis in periodontitis
Periodontitis is characterized by persistent inflammation and impaired periodontal regeneration, but the mechanism linking these processes remains unclear. Here, we identified a pa...
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss
Abstract
Semaglutide is often optimized for weight loss, but whether longer-term cardiovascular benefit tracks achieved weight loss or therapeutic exposure levels r...
[RETRACTED] Prima Weight Loss Dragons Den UK v1
[RETRACTED] Prima Weight Loss Dragons Den UK v1
[RETRACTED]Prima Weight Loss Dragons Den UK :-Obesity is a not kidding medical issue brought about by devouring an excessive amount of fat, eating terrible food sources, and practi...
[RETRACTED] Prima Weight Loss Dragons Den UK v1
[RETRACTED] Prima Weight Loss Dragons Den UK v1
[RETRACTED]Prima Weight Loss Dragons Den UK :-Obesity is a not kidding medical issue brought about by devouring an excessive amount of fat, eating terrible food sources, and practi...
The craze with Semaglutide
The craze with Semaglutide
Semaglutide (Ozempic acid) belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. These medications mimic the action of a hormone called GLP-1, which...
The craze with semaglutide
The craze with semaglutide
Semaglutide (Ozempic acid) belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. These medications mimic the action of a hormone called GLP-1, which...
Safety of Semaglutide
Safety of Semaglutide
The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutan...

